Overview

Efficacy of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Patients

Status:
Not yet recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of DTG + 3TC versus DTG + TDF/FTC over 48 weeks in HIV-1 naive patients in a real life setting with no baseline HIV genotypic resistance testing available.

Phase:

Phase 4

Details

Lead Sponsor:

Fundacion IDEAA

Collaborator:

ViiV Healthcare

Treatments:

Dolutegravir
Emtricitabine
Lamivudine
Tenofovir